跳至主要内容
临床试验/NCT02718001
NCT02718001进行中(未招募)不适用

Edwards EVOQUE Eos Mitral Valve Replacement: Investigation of Safety and Performance After Mitral Valve Replacement With Transcatheter Device (MISCEND)

Edwards Lifesciences29 个研究点 分布在 2 个国家目标入组 123 人开始时间: 2015年2月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
123
试验地点
29
主要终点
Composite of major adverse events

研究概览

简要总结

Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system

详细描述

The study is a multi-center, prospective, single-arm, and non-randomized study designed to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinically significant, symptomatic mitral regurgitation
  • High risk for open-heart surgery
  • Meets anatomical criteria

排除标准

  • Unsuitable anatomy
  • Patient is inoperable

研究组 & 干预措施

Treatment

Experimental

Treatment with the Edwards EVOQUE Eos mitral valve replacement system

干预措施: Edwards EVOQUE Eos Mitral Valve Replacement System (Device)

结局指标

主要结局

Composite of major adverse events

时间窗: 30 days

Proportion of patients with major adverse events

次要结局

  • NYHA functional class(30 days, 6 Months, 12 Months, annual for five years)
  • Clinical Success(30 days)
  • Procedural Success(Discharge or 7 days post-procedure, whichever occurs first)
  • Reduction in MR grade(30 days, 6 Months, 12 Months, annual for five years)
  • Device Success(Immediately after procedure)
  • Six minute walk test(30 days, 6 Months, 12 Months, annual for five years)

研究者

发起方
Edwards Lifesciences
申办方类型
Industry
责任方
Sponsor

研究点 (29)

Loading locations...

相似试验

Edwards EVOQUE Eos MISCEND Study | 临床试验